WILMINGTON, Mass., March 12, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today its QS-H150 handheld explosives trace detector has received an important regulatory certification in China from the Chinese Ministry of Public Security. This marks the latest in a series of key product certifications for Implant Sciences, including STAC in France and TSA’s qualification for air cargo screening in the US.

Implant Sciences has been active in the China market for several years. China represents an important market for the Company, one where it has generated over $20 million in sales to date. Its explosives trace detectors have been deployed at the 2008 Beijing Olympics, Beijing subway stations, and are in use for aviation security and critical infrastructure protection. In July 2013, the Company opened a representative office in Shanghai.

“This Ministry of Public Security certification opens the doors for us to compete for additional public security contracts issued by the Chinese government. We believe this will significantly expand our sales opportunities in China, where we already have a strong presence and our products have a stellar reputation for performance and cost efficiency,” stated Glenn D. Bolduc, Implant Sciences’ President and CEO.

Implant Sciences’ Vice President of Sales and Marketing, Dr. Darryl Jones, added, “The results of these stringent certification tests further demonstrate the strength of our QS-H150. Notable accomplishments in the testing were the very rapid clear-down time, which is essential for high traffic screening areas, the large number and variety of explosives detected at minute levels, and the system’s performance in a wide range of temperatures and environments.”

BOTHELL, WA–(Marketwired – Mar 10, 2014) – Borneo Resource Investments Ltd. (OTCQB: BRNE) (the “Company” or “Borneo”), a mining company that mines gold and develops producing gold mines as well as coal mining properties in Indonesia, today announced it has begun full production on its Ratatotok South gold property. Ratatotok South, which was acquired through Borneo’s subsidiary PT Puncak Kalabat in December 2013, becomes the Company’s second producing gold mine.

Two successful test runs were completed at Ratatotok South in January and February, setting the stage for full production to begin in March. Approximately 2,500 metric tons of high grade ore have been excavated in the last few weeks and positioned in the heapleach containment area. Up to three processing cycles will be run on the ore to extract all of the gold it contains. At the end of each processing cycle the ore enhanced carbon will be moved from the site to the Company’s facilities in Manado for final processing.

“I am very pleased that we were able to move from acquisition, through the processing trials and to full production at Ratatotok South so quickly. Our team was able to fine tune the production process during the trials and our geologists supervised the excavation of a high grade ore body on the property for our first production run,” commented Borneo CEO Nils Ollquist.

Mr. Ollquist went on to say, “Our geologists estimate the ore grade to be 2 to 3 grams of gold per metric ton. The estimated production output from 2,500 metric tons of ore for the first full production run is approximately 7 kg of 80% pure gold. Our intention is to continue to upgrade and refine our production capabilities and to expand our portfolio of high quality properties in the area.”

About Borneo Resource Investments Ltd.

Borneo Resource Investments Ltd. (OTCQB: BRNE) is a mining company that mines gold and develops producing gold mines as well as coal mining properties in the Republic of Indonesia. Borneo’s current assets include three gold properties, two of which are producing gold. Cash flow-producing investments in gold properties help fund Borneo’s operations and investments in gold, while the Company develops high value, longer-term investments in thermal “coal concessions,” which are properties that can be mined for coal. Borneo currently has one coal concession in the Borneo region of Indonesia. Indonesia was the 8th largest gold producing nation in 2012 and the world’s largest exporter of coal, with $25 billion exported in 2012.

JERUSALEM, March 11, 2014 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that IP Australia, the Australian government’s patent office, has issued the Company its third patent in the country. The patent, titled “Methods and Compositions for Oral Administration of Exenatide,” covers oral exenatide compositions made using the company’s proprietary technology, including its ORMD-0901 oral exenatide capsule.

Oramed has planned a comprehensive clinical program for ORMD-0901, with the goal of seeking approval in the U.S. and other territories. IND-enabling toxicity studies are scheduled to begin later this year in the U.S. and a Phase 1b study outside of the U.S. is also planned for 2014.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral GLP-1 analog capsule (ORMD-0901). Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company’s corporate and R&D headquarters are based in Jerusalem.

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

The study is still ongoing and the maximal tolerated dose (MTD) has not yet been achieved. Three dosing cycles have been completed (25, 50 and 100 mg) and no drug related adverse events have been reported. The fourth dosing cycle (150 mg) has been initiated. Two patients have received 2 cycles of treatment and one patient has received 6 cycles of treatment. Pharmacokinetic analysis has shown that SupinoxinTM displays dose-proportional exposure and an estimated oral bioavailability of 51%. The pharmacokinetic profile of Supinoxin is similar to what has been seen in preclinical studies.

Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer commented, “We are encouraged that Supinoxin is safe and well-tolerated over the dose range tested in cancer patients with solid tumors who have received multiple cycles of treatment. In addition, the pharmacokinetic profile and oral bioavailability of Supinoxin is consistent with preclinical studies. These data are very encouraging, and we look forward to sharing additional data from the trial when it is completed later this year.”

The Phase I trial of Supinoxin, which was initiated in August 2013, is a dose-escalation study which will evaluate the safety, tolerability, dose-limiting toxicities and MTD in patients with solid cancer tumors that have previously failed treatment with approved therapies and shown progression of disease. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. This trial is being conducted in three clinical oncology centers in the United States. Each patient has the ability to continue on the drug up to six cycles of treatment (a dosing cycle is defined as 3 weeks of drug treatment followed by and 1 week off) if no disease progression is seen. Patients are assessed by CT or MRI prior to the start of therapy and after every two cycles of therapy to assess tumor progression. The trial is using an accelerated dose-escalation design: one patient is treated per dose cycle until a grade 2 related adverse event occurs then three patients will be treated per dose cycle. The decision to escalate dose is made by the DMSB after completion of one cycle of treatment based on safety and tolerability. Patients have the possibility to receive up to 6 cycles of treatment if the disease does not progress. Tumor biopsy samples are taken to assess the biomarker phospho-P68.